<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00872950</url>
  </required_header>
  <id_info>
    <org_study_id>2001-040</org_study_id>
    <nct_id>NCT00872950</nct_id>
  </id_info>
  <brief_title>3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)</brief_title>
  <acronym>LEMS</acronym>
  <official_title>Open Label Trial Of 3,4-Diaminopyridine In Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndromes (CMS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lahey Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lahey Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness and adverse effects of
      3,4-diaminopyridine for the treatment of the Lambert-Eaton Myasthenic Syndrome (LEMS) and
      Congenital Myasthenic Syndromes (CMS).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2001</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in strength and autonomic symptoms</measure>
    <time_frame>1-10 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Lambert-Eaton Myasthenic Syndrome</condition>
  <condition>Congenital Myasthenic Syndrome</condition>
  <arm_group>
    <arm_group_label>Open label</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3,4-DIAMINOPYRIDINE</intervention_name>
    <description>Treatment will begin with a low dose and will be increased as clinically needed as tolerated. The upper limit will be a total of 100mg/day.</description>
    <arm_group_label>Open label</arm_group_label>
    <other_name>3,4 DAP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3,4-Diaminopyridine</intervention_name>
    <arm_group_label>Open label</arm_group_label>
    <other_name>3,4-DAP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  LEMS diagnosis OR Pre or Post Synaptic CMS diagnosis

          -  18 years or older

          -  Females must have negative pregnancy test and be willing to practice an effective form
             of birth control

          -  No prolonged QT syndrome as indicated by baseline EKG

        Exclusion Criteria:

          -  Known sensitivity to 3,4-DIAMINOPYRIDINE

          -  History of seizures and/or severe asthma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jayashri Srinivasan, MD, MCRP, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lahey Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>H. Royden Jones, MD</last_name>
    <role>Study Director</role>
    <affiliation>Lahey Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nick F Ventura</last_name>
    <phone>781-744-3216</phone>
    <email>Nicholas.F.Ventura@lahey.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephanie A Scala, MA</last_name>
    <phone>781-744-2950</phone>
    <email>stephanie.a.scala@lahey.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lahey Clinic</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn A Sullivan</last_name>
      <phone>781-744-2958</phone>
      <email>lynn.a.sullivan@lahey.org</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie A Scala, MA</last_name>
      <phone>781-744-2950</phone>
      <email>stephanie.a.scala@lahey.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lahey.org</url>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2009</study_first_submitted>
  <study_first_submitted_qc>March 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2009</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LEMS</keyword>
  <keyword>CMS</keyword>
  <keyword>3,4 DIAMINOPYRIDINE</keyword>
  <keyword>3,4 DAP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Lambert-Eaton Myasthenic Syndrome</mesh_term>
    <mesh_term>Myasthenic Syndromes, Congenital</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>3,4-diaminopyridine</mesh_term>
    <mesh_term>4-Aminopyridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

